AGN - Allergan plc

NYSE - NYSE Delayed Price. Currency in USD
188.28
-0.99 (-0.52%)
At close: 4:01PM EDT

187.75 -0.53 (-0.28%)
After hours: 4:53PM EDT

Stock chart is not supported by your current browser
Previous Close189.27
Open190.59
Bid187.30 x 200
Ask188.19 x 100
Day's Range187.06 - 192.01
52 Week Range182.80 - 256.80
Volume4,753,688
Avg. Volume2,772,492
Market Cap62.94B
Beta1.26
PE Ratio (TTM)5.74
EPS (TTM)32.82
Earnings DateNov 1, 2017
Forward Dividend & Yield2.80 (1.42%)
Ex-Dividend Date2017-08-16
1y Target Est250.72
Trade prices are not sourced from all markets
  • Market Realist48 minutes ago

    Allergan Stock: Performance in 3Q17

    Allergan stock has fallen ~15.4% in 3Q17. It has fallen 9.8% year-to-date as of October 20, 2017.

  • Barrons.com3 hours ago

    Allergan: A Splitting Headache?

    Another analyst is weighing in on the growing guesswork regarding the likelihood that Allergan (AGN) could be heading for a break up. Allergan is appealing the decision, though the outcome of such a move is far from certain. Meanwhile, several analysts warn that a cheaper-priced generic version of Restasis could hit the U.S. market next year, eroding sales of Allergan’s second-biggest selling drug and creating a $1.5 billion revenue hole.

  • Pharma Stock Roundup: Beat & Raise Quarter from J&J, Allergan Hit by Restasis Ruling
    Zacks9 hours ago

    Pharma Stock Roundup: Beat & Raise Quarter from J&J, Allergan Hit by Restasis Ruling

    Johnson & Johnson's (JNJ) Q3 earnings results were the key highlight this week with the company reporting strong results and raising its outlook.

  • Reuters18 hours ago

    Imprimis Pharma to take on Allergan's Restasis with cheaper product

    San Diego-based Imprimis' therapy will cost 99 cents for a month's supply, with refills starting at $79 a month and the company will start selling prescriptions on Nov. 1, Imprimis' Chief Executive Mark Baum told Reuters. Allergan recently stirred controversy after striking a deal with the Native American Saint Regis Mohawk tribe that would shield certain patents on Restasis.

  • TheStreet.comyesterday

    Allergan's Hard Fall Is Not Enough of a Reason to Buy

    AGN could make a capitulation low but it is a long way from making a bottom formation.

  • Barrons.comyesterday

    Allergan: All In or Fall Out?

    Is Allergan (AGN) worth the risk? That’s the question analysts and investors are tackling this week after the drug maker got rocked by a federal court ruling that invalidated some of the patents protecting ...

  • Company News For Oct 19, 2017
    Zacksyesterday

    Company News For Oct 19, 2017

    Companies in the News are: FOGO,ABT,AGN,EA

  • Conatus Entrusts Keith W. Marshall With Key Management Roles
    Zacksyesterday

    Conatus Entrusts Keith W. Marshall With Key Management Roles

    Conatus Pharmaceuticals (CNAT) announced the appointment of Keith W. Marshall as executive vice president, chief operating officer and chief financial officer.

  • PR Newswire2 days ago

    Allergan Issues Investor FAQ on Federal District Court RESTASIS® Patent Decision

    Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry with 65+ mid-to-late stage pipeline programs currently in development.

  • Barrons.com2 days ago

    The Biggest Loser: Allergan's Patent Troubles

    Allergan (AGN) fell to the bottom of the S&P 500 today as analysts predicted that the drug maker’s blockbuster eye drug Restasis could see a generic rival as soon as next year. Shares of Allergan fell more than 5.3% to close at $187.15 a share, on a day when the index edged 0.7% lower. On Monday, Allergan got rocked when a federal judge invalidated some of the patents protecting Restasis, opening the door for generic rivals that could push Allergan’s second-biggest selling drug off a cliff.

  • Why SUPERVALU, Synchronoss Technologies, and Allergan Slumped Today
    Motley Fool2 days ago

    Why SUPERVALU, Synchronoss Technologies, and Allergan Slumped Today

    Even as the market climbed, these stocks lagged behind. Find out why.

  • US cash equities are the best risk-adjusted rate return in town: NYSE trader
    Yahoo Finance Video4 hours ago

    US cash equities are the best risk-adjusted rate return in town: NYSE trader

    Keith Bliss of Cuttone and Company joins Yahoo Finance's Alexis Christoforous from the floor of the New York Stock Exchange to discuss the current rally in stocks and the importance of tax cuts.

  • Mohawk Tribe sues Microsoft, Amazon for patent infringeme...
    CNBC Videos2 days ago

    Mohawk Tribe sues Microsoft, Amazon for patent infringeme...

    CNBC's Meg Tirrell reports on the latest patent lawsuits from the Saint Regis Mohawk Tribe.

  • 4 health stocks and a gamer in the Blitz
    CNBC Videos2 days ago

    4 health stocks and a gamer in the Blitz

    Big movers in today's blitz